Chattanooga Oncology and Hematology Associates — Chattanooga, Tennessee

Chattanooga Oncology and Hematology Associates is a clinical research site located in Chattanooga, Tennessee, United States.

Crixeo Clinical Trials Trust Score: 17/100 (FAILING). This profile has not yet been claimed by the site owner.

Chattanooga Oncology and Hematology Associates has participated in 11 clinical trials.

Therapeutic areas: Prostate Cancer, HER2 Positive Esophagogastric Cancer, Leukemia.

Sponsors: Achieve Life Sciences, SCRI Development Innovations, LLC, Wake Forest University Health Sciences.

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Chattanooga

Browse all research sites in Tennessee · View every site in Chattanooga

Sponsor Feasibility Report

Trust Score: 17/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Chattanooga Oncology and Hematology Associates?

Chattanooga Oncology and Hematology Associates has a Crixeo Trust Score of 17/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Chattanooga Oncology and Hematology Associates conducted?

Chattanooga Oncology and Hematology Associates has 11 clinical trials on record. Their work covers Prostate Cancer, HER2 Positive Esophagogastric Cancer, Leukemia.

Is Chattanooga Oncology and Hematology Associates accredited by Crixeo Clinical Trials?

Chattanooga Oncology and Hematology Associates has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Chattanooga Oncology and Hematology Associates?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.